Fig. 6
From: Emerging phagocytosis checkpoints in cancer immunotherapy

CD47-SIRPα pathway. a CD47 expressed on tumor cells interacts with SIRPα expressed on macrophages and other phagocytes to avoid immune surveillance. b Targeting CD47 or blocking the CD47-SIRPα axis interrupts their interaction and allows macrophages to phagocyte tumor cells. c CD47 expressed on hematopoietic cells or red blood cells interacts with SIRPα expressed on macrophages and other phagocytes to avoid phagocytosis. d Targeting CD47 or interrupting the CD47-SIRPα axis allows macrophages to phagocyte hematopoietic cells and thus brings the side effects such as anemia